Literature DB >> 11399594

BMT: Serum Ferritin as Risk Factor for Veno-occlusive Disease of the Liver. Prospective Cohort Study.

M. Morado1, E. Ojeda, J. Garcia-Bustos, M. J. Aguado, R. Arrieta, E. Quevedo, A. Navas, F. Hernandez-Navarro.   

Abstract

Veno-occlusive disease of the liver (VOD) is an important complication in hematological transplantation. The aim of this study is to analyze the risk factors for VOD and other forms of liver toxicity in a cohort of 180 peripheral stem cell transplants performed in our Center. We find that elevated pretransplant levels of serum ferritin are the most important risk marker for VOD. We believe that ferritin reflects damage induced by oxygen radicals resulting from iron-mediated catalysis. We also discuss different risk factors for VOD and other forms of liver toxicity, suggesting diferent pathogenic mechanisms.

Entities:  

Year:  2000        PMID: 11399594

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  14 in total

1.  Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation.

Authors:  John Koreth; Joseph H Antin
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

Review 2.  An update on iron chelation therapy.

Authors:  Erika Poggiali; Elena Cassinerio; Laura Zanaboni; Maria Domenica Cappellini
Journal:  Blood Transfus       Date:  2012-06-27       Impact factor: 3.443

3.  Does iron overload really matter in stem cell transplantation?

Authors:  Philippe Armand; Marie-Michele Sainvil; Haesook T Kim; Joanna Rhodes; Corey Cutler; Vincent T Ho; John Koreth; Edwin P Alyea; Ellis J Neufeld; Raymond Y Kwong; Robert J Soiffer; Joseph H Antin
Journal:  Am J Hematol       Date:  2012-04-04       Impact factor: 10.047

4.  Experience from a single paediatric transplant centre with identification of some protective and risk factors concerning the development of hepatic veno-occlusive disease in children after allogeneic hematopoietic stem cell transplant.

Authors:  N Maximova; G Ferrara; M Minute; A Pizzol; V Kiren; M Montico; M Gregori; P Tamaro
Journal:  Int J Hematol       Date:  2014-04-09       Impact factor: 2.490

5.  Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation.

Authors:  Philippe Armand; Haesook T Kim; Joanna Rhodes; Marie-Michele Sainvil; Corey Cutler; Vincent T Ho; John Koreth; Edwin P Alyea; Doreen Hearsey; Ellis J Neufeld; Mark D Fleming; Hanno Steen; Damon Anderson; Raymond Y Kwong; Robert J Soiffer; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-18       Impact factor: 5.742

6.  Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation.

Authors:  Philippe Armand; Haesook T Kim; Corey S Cutler; Vincent T Ho; John Koreth; Edwin P Alyea; Robert J Soiffer; Joseph H Antin
Journal:  Blood       Date:  2007-01-18       Impact factor: 22.113

7.  Iron overload in patients undergoing hematopoietic stem cell transplantation.

Authors:  Vinod Pullarkat
Journal:  Adv Hematol       Date:  2010-09-08

8.  Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content.

Authors:  Bryan J Trottier; Linda J Burns; Todd E DeFor; Sarah Cooley; Navneet S Majhail
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

9.  Pharmacogenetic study of deferasirox, an iron chelating agent.

Authors:  Ji Won Lee; Hyoung Jin Kang; Ji-Yeob Choi; Nam Hee Kim; Mi Kyung Jang; Chang-Woo Yeo; Sang Seop Lee; Hyery Kim; June Dong Park; Kyung Duk Park; Hee Young Shin; Jae-Gook Shin; Hyo Seop Ahn
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240

10.  Differential regulation of ferritin subunits and iron transport proteins: an effect of targeted hepatic X-irradiation.

Authors:  Naila Naz; Shakil Ahmad; Silke Cameron; Federico Moriconi; Margret Rave-Fränk; Hans Christiansen; Clemens Friedrich Hess; Giuliano Ramadori; Ihtzaz A Malik
Journal:  Biomed Res Int       Date:  2013-12-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.